Clinofibrate improved canine lipid metabolism in some but not all breeds

J Vet Med Sci. 2018 Jun 29;80(6):945-949. doi: 10.1292/jvms.17-0703. Epub 2018 Mar 26.

Abstract

The objectives of this study were to assess if Clinofibrate (CF) treatment improved lipid metabolism in dogs, and to clarify whether its efficacy is influenced by canine characteristics. We collected medical records of 306 dogs and performed epidemiological analyses. Lipid values of all lipoproteins were significantly decreased by CF medication, especially VLDL triglyceride (TG) concentration (mean reduction rate=54.82%). However, 17.65% of dogs showed drug refractoriness in relation to TG level, and Toy Poodles had a lower CF response than other breeds (OR=5.36, 95% CI=2.07-13.90). Therefore, our study suggests that genetic factors may have an effect on CF response, so genetic studies on lipid metabolism-related genes might be conducted to identify variations in CF efficacy.

Keywords: Toy Poodle; clinofibrate; descriptive epidemiology; drug response; dyslipidemia.

MeSH terms

  • Animals
  • Breeding*
  • Dogs / metabolism*
  • Female
  • Lipid Metabolism / drug effects*
  • Lipid Metabolism / physiology*
  • Lipoproteins
  • Lipoproteins, VLDL
  • Male
  • Phenoxyacetates / pharmacology*
  • Triglycerides

Substances

  • Lipoproteins
  • Lipoproteins, VLDL
  • Phenoxyacetates
  • Triglycerides
  • clinofibrate